These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 32882428)

  • 21. The Role of Three-Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery.
    Allen AM; Shah VH; Therneau TM; Venkatesh SK; Mounajjed T; Larson JJ; Mara KC; Schulte PJ; Kellogg TA; Kendrick ML; McKenzie TJ; Greiner SM; Li J; Glaser KJ; Wells ML; Chen J; Ehman RL; Yin M
    Hepatology; 2020 Feb; 71(2):510-521. PubMed ID: 30582669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inter-reader agreement of magnetic resonance imaging proton density fat fraction and its longitudinal change in a clinical trial of adults with nonalcoholic steatohepatitis.
    Hooker JC; Hamilton G; Park CC; Liao S; Wolfson T; Dehkordy SF; Hong CW; Mamidipalli A; Gamst A; Loomba R; Sirlin CB
    Abdom Radiol (NY); 2019 Feb; 44(2):482-492. PubMed ID: 30128694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis.
    Alsaqal S; Hockings P; Ahlström H; Gummesson A; Hedström A; Hulthe J; Johansson L; Niessen HG; Schoelch C; Schultheis C; Vessby J; Wanders A; Rorsman F; Ebeling Barbier C
    J Magn Reson Imaging; 2022 Aug; 56(2):368-379. PubMed ID: 34953171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease.
    Bashir MR; Wolfson T; Gamst AC; Fowler KJ; Ohliger M; Shah SN; Alazraki A; Trout AT; Behling C; Allende DS; Loomba R; Sanyal A; Schwimmer J; Lavine JE; Shen W; Tonascia J; Van Natta ML; Mamidipalli A; Hooker J; Kowdley KV; Middleton MS; Sirlin CB;
    J Magn Reson Imaging; 2019 May; 49(5):1456-1466. PubMed ID: 30318834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials.
    Noureddin M; Lam J; Peterson MR; Middleton M; Hamilton G; Le TA; Bettencourt R; Changchien C; Brenner DA; Sirlin C; Loomba R
    Hepatology; 2013 Dec; 58(6):1930-40. PubMed ID: 23696515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD.
    Permutt Z; Le TA; Peterson MR; Seki E; Brenner DA; Sirlin C; Loomba R
    Aliment Pharmacol Ther; 2012 Jul; 36(1):22-9. PubMed ID: 22554256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRI proton density fat fraction is robust across the biologically plausible range of triglyceride spectra in adults with nonalcoholic steatohepatitis.
    Hong CW; Mamidipalli A; Hooker JC; Hamilton G; Wolfson T; Chen DH; Fazeli Dehkordy S; Middleton MS; Reeder SB; Loomba R; Sirlin CB
    J Magn Reson Imaging; 2018 Apr; 47(4):995-1002. PubMed ID: 28851124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-invasive evaluation of NAFLD and the contribution of genes: an MRI-PDFF-based cross-sectional study.
    Yang A; Zhu X; Zhang L; Zhang Y; Zhang D; Jin M; Niu J; Zhang H; Ding Y; Lv G
    Hepatol Int; 2022 Oct; 16(5):1035-1051. PubMed ID: 35829866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis.
    Andersson A; Kelly M; Imajo K; Nakajima A; Fallowfield JA; Hirschfield G; Pavlides M; Sanyal AJ; Noureddin M; Banerjee R; Dennis A; Harrison S
    Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2451-2461.e3. PubMed ID: 34626833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of a high-SNR chemical-shift-encoded MRI with complex reconstruction for proton density fat fraction (PDFF) estimation overall and in the low-fat range.
    Park CC; Hooker C; Hooker JC; Bass E; Haufe W; Schlein A; Covarrubias Y; Heba E; Bydder M; Wolfson T; Gamst A; Loomba R; Schwimmer J; Hernando D; Reeder SB; Middleton M; Sirlin CB; Hamilton G
    J Magn Reson Imaging; 2019 Jan; 49(1):229-238. PubMed ID: 29707848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis.
    Tang A; Tan J; Sun M; Hamilton G; Bydder M; Wolfson T; Gamst AC; Middleton M; Brunt EM; Loomba R; Lavine JE; Schwimmer JB; Sirlin CB
    Radiology; 2013 May; 267(2):422-31. PubMed ID: 23382291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease.
    Tang A; Desai A; Hamilton G; Wolfson T; Gamst A; Lam J; Clark L; Hooker J; Chavez T; Ang BD; Middleton MS; Peterson M; Loomba R; Sirlin CB
    Radiology; 2015 Feb; 274(2):416-25. PubMed ID: 25247408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease.
    Idilman IS; Keskin O; Celik A; Savas B; Elhan AH; Idilman R; Karcaaltincaba M
    Acta Radiol; 2016 Mar; 57(3):271-8. PubMed ID: 25855666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective comparison of longitudinal change in hepatic proton density fat fraction (PDFF) estimated by magnitude-based MRI (MRI-M) and complex-based MRI (MRI-C).
    Mamidipalli A; Fowler KJ; Hamilton G; Wolfson T; Covarrubias Y; Tran C; Fazeli S; Wiens CN; McMillan A; Artz NS; Funk LM; Campos GM; Greenberg JA; Gamst A; Middleton MS; Schwimmer JB; Reeder SB; Sirlin CB
    Eur Radiol; 2020 Sep; 30(9):5120-5129. PubMed ID: 32318847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
    Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
    J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
    Bril F; Barb D; Lomonaco R; Lai J; Cusi K
    J Hepatol; 2020 Mar; 72(3):401-410. PubMed ID: 31589891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative Ultrasound Radiofrequency Data Analysis for the Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Using Magnetic Resonance Imaging Proton Density Fat Fraction as the Reference Standard.
    Jeon SK; Lee JM; Joo I; Park SJ
    Korean J Radiol; 2021 Jul; 22(7):1077-1086. PubMed ID: 33739636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease.
    Middleton MS; Van Natta ML; Heba ER; Alazraki A; Trout AT; Masand P; Brunt EM; Kleiner DE; Doo E; Tonascia J; Lavine JE; Shen W; Hamilton G; Schwimmer JB; Sirlin CB;
    Hepatology; 2018 Mar; 67(3):858-872. PubMed ID: 29028128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between Visceral Adipose Tissue and Non-Alcoholic Steatohepatitis Histology in Patients with Known or Suspected Non-Alcoholic Fatty Liver Disease.
    Idilman IS; Low HM; Gidener T; Philbrick K; Mounajjed T; Li J; Allen AM; Yin M; Venkatesh SK
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34200525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Ajmera V; Park CC; Caussy C; Singh S; Hernandez C; Bettencourt R; Hooker J; Sy E; Behling C; Xu R; Middleton MS; Valasek MA; Faulkner C; Rizo E; Richards L; Sirlin CB; Loomba R
    Gastroenterology; 2018 Aug; 155(2):307-310.e2. PubMed ID: 29660324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.